UCB DESIGNATES DRUG TO TREAT MYOCLONIC EPILEPSY

Belgian biopharma company UCB (UCBBt.BR: Quote, Profile, Research) said on Monday that European regulators had approved its plans to designate its brivaracetam epilepsy drug as a medicine to treat rare life-threatening conditions. UCB is developing brivaracetam as a successor to its Keppra anti-epileptic drug. The European Medicines Agency (EMEA) approved UCB's plan to designate it as an "orphan medicinal product" to treat progressive myoclonic epilepsies, a form of epilepsy caused by rare disorders.

Reuters (http://today.reuters.com/business/newsArticle.aspx?type=health&storyID=nL25544027)